{"nctId":"NCT00943098","briefTitle":"Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery","startDateStruct":{"date":"2009-09"},"conditions":["Dental Pain"],"count":142,"armGroups":[{"label":"Diclofenac HPBCD s.c. 75mg/ml","type":"EXPERIMENTAL","interventionNames":["Drug: Diclofenac HPBCD s.c. 75mg/ml"]},{"label":"Voltarol 75mg/3ml i.m.","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Voltarol 75mg/3ml i.m."]}],"interventions":[{"name":"Diclofenac HPBCD s.c. 75mg/ml","otherNames":[]},{"name":"Voltarol 75mg/3ml i.m.","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients undergoing surgical extraction of a single fully or partially impacted mandibular 3rd molar requiring bone removal.\n* Patients experiencing moderate to severe post-operative pain within 6 hours from end of surgery.\n* Pre-operative laboratory tests in the reference ranges or without clinically significant abnormalities as judged by the Investigator.\n\nExclusion Criteria:\n\n* Surgery performed under general anaesthesia, or sedation.\n* Complications occurring during the surgical procedure or in the period before randomisation as judged by the investigator.\n* Acute local or systemic infection at the time of surgery that could confound the post-surgical evaluation.\n* Patients with clinical signs of gastritis, gastro-duodenal ulcer, GI bleeding. Other GI disturbances or disease that in the opinion of the investigator could be negatively affected by the administration of NSAIDs.\n* Clinical signs or history of coagulation disorders that could be negatively affected by NSAIDs administration.\n* Hepatic or renal impairment.\n* Patients with significant cardiac impairment, history of cerebrovascular disease, history or peripheral arterial disease, uncontrolled hypertension.\n* Hypersensitivity to diclofenac or other NSAIDs or to one of the study medication components.\n* Patients under chronic treatment with topical or systemic analgesics/NSAIDs.\n* Patients under treatment with any medication that may affect the treatment efficacy evaluation.\n* Patients under treatment with any medication whose concomitant use may be susceptible to interactions with diclofenac or may affect safety.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain Intensity Difference (PID)","description":"Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assessed by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.8","spread":"40.5 to 49.1"},{"groupId":"OG001","value":"45.5","spread":null}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.37","spread":"13.1"},{"groupId":"OG001","value":"6.83","spread":"15.6"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":"17.1"},{"groupId":"OG001","value":"18.4","spread":"18.9"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":"18.8"},{"groupId":"OG001","value":"37.9","spread":"19.6"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":"18.8"},{"groupId":"OG001","value":"37.9","spread":"19.6"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":"18.4"},{"groupId":"OG001","value":"45.0","spread":"17.9"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":"16.0"},{"groupId":"OG001","value":"50.3","spread":"16.1"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.7","spread":"17.0"},{"groupId":"OG001","value":"53.3","spread":"15.0"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6","spread":"14.6"},{"groupId":"OG001","value":"53.9","spread":"15.5"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7","spread":"15.7"},{"groupId":"OG001","value":"52.3","spread":"15.6"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":"14.4"},{"groupId":"OG001","value":"51.2","spread":"16.3"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.8","spread":"17.2"},{"groupId":"OG001","value":"49.6","spread":"18.2"}]}]}]},{"type":"SECONDARY","title":"PIDs","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":"15.8"},{"groupId":"OG001","value":"47.1","spread":"17.9"}]}]}]},{"type":"PRIMARY","title":"Pain Intensity Difference (PID)","description":"Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assessed by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null},{"groupId":"OG001","value":"44.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":70},"commonTop":["Injection site pain","Headache","Nausea","injection site haematoma","Injection site reaction"]}}}